Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:26:14 EDT Tue 08 Oct 2024
Enter Symbol
or Name
USA
CA



News for U:APTO from 2023-10-09 to 2024-10-08 - 23 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-09-05 16:15U:APTONews ReleaseAptose Announces Results from Special Meeting of Shareholders
2024-08-30 16:30U:APTONews ReleaseAptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
2024-08-15 16:30U:APTONews ReleaseAptose Announces Adjournment of its Special Meeting of Shareholders
2024-08-08 17:07U:APTONews ReleaseAptose Reports Results for the Second Quarter 2024
2024-07-19 17:00U:APTONews ReleaseAptose Announces Receipt of Deficiency Notice from Nasdaq
2024-06-18 17:30U:APTONews ReleaseAptose Announces Results from Annual and Special Meeting of Shareholders
2024-06-14 07:30U:APTONews ReleaseAptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
2024-06-03 16:30U:APTONews ReleaseAptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2024-05-31 08:00U:APTONews ReleaseAptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2024-05-14 16:01U:APTONews ReleaseAptose Reports Results for the First Quarter 2024
2024-05-06 16:30U:APTONews ReleaseAptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
2024-03-26 16:01U:APTONews ReleaseAptose Reports Results for the Fourth Quarter and Full Year 2023
2024-03-18 16:30U:APTONews ReleaseAptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
2024-01-31 16:01U:APTONews ReleaseAptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
2024-01-26 08:00U:APTONews ReleaseAptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
2023-12-09 18:30U:APTONews ReleaseAptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
2023-11-30 17:00U:APTONews ReleaseAptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
2023-11-09 16:00U:APTONews ReleaseAptose Reports Results for the Third Quarter 2023
2023-11-02 09:00U:APTONews ReleaseAptose Tuspetinib Clinical Data Selected for Oral Presentation ‚  at the 2023 ASH Annual Meeting
2023-10-30 09:15U:APTONews ReleaseAptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
2023-10-26 07:11U:APTONews ReleaseAptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
2023-10-23 07:30U:APTONews ReleaseAptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
2023-10-16 07:30U:APTONews ReleaseAptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference